Novel oral anticoagulants in intracardiac thrombosis resolution: a case series

Mohammed Al-Sadawi1, Jonathan Francois1, Romy Rodriguez Ortega1

  • 1Department of Internal Medicine, SUNY Downstate, 450 Clarkson Ave Box 1199, Brooklyn, NY 11203, USA.

Insights

Direct oral anticoagulants (DOACs) show promise for treating intracardiac thrombosis, offering potential for superior thrombus resolution compared to traditional therapies. This study supports DOACs as an effective option for left atrial appendage thrombi.

Area of Science:

  • Cardiology
  • Hematology
  • Pharmacology

Background:

  • Vitamin K antagonists (VKAs) have historically been the standard treatment for intracardiac thrombosis, primarily based on observational data.
  • Direct oral anticoagulants (DOACs) are now first-line for many thrombotic conditions, but their role in intracardiac thrombosis is still evolving.
  • Emerging evidence suggests DOACs may be effective, potentially offering better thrombus resolution than warfarin.

Purpose of the Study:

  • To evaluate the efficacy of direct oral anticoagulants (DOACs) in treating left atrial appendage thrombi.
  • To contribute to the growing body of evidence supporting DOACs for intracardiac thrombosis.

Main Methods:

  • A case series of six patients with left atrial appendage thrombi was analyzed.
  • Patients were treated with a standard venous thromboembolic dose of DOACs.

Main Results:

  • Complete resolution of left atrial appendage thrombi was observed in all six patients.
  • Thrombus resolution occurred within a 2-6 month treatment period.
  • No complications were reported during the treatment course.

Conclusions:

  • This case series supports the use of DOACs as an effective treatment for intracardiac thrombi.
  • DOACs represent a viable alternative for managing left atrial appendage thrombosis.
Abstract

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.7K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
144
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.3K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
107
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
146
Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
112